Peter Young

Articles

Biopharma M&A: Year in Review, Ripples Ahead

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.